ACCM meeting #24, 19 March 2020

The meeting of the Advisory Committee on Complementary Medicines (ACCM).

The committee's advice and comment was sought on:

• Aspects of clinical trial data that are critical to make publicly available as part of conducting a clinical trial with regard to the TGA's proposed data protection scheme for assessed listed medicines.
• Whether listed medicines containing higher doses of various forms of magnesium should carry a label warning for potential laxative effects and whether an upper intake limit is necessary.
• Whether Fallopia multiflora has been established as a cause of herb-induced liver injury, and whether there is sufficient evidence to support restrictions to mitigate the risk of liver injury when used in listed medicines.

Members

Membership comprises of professionals with specific scientific, medical, clinical expertise as well as appropriate consumer health issues relating to complementary medicines.